The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis

References

• Agbogbo, F. K., Ecker, D. M., Farrand, A., Han, K., Khoury, A., Martin, A., McCool, J., Rasche, U., Rau, T. D., Schmidt, D., Sha, M., & Treuheit, N. (2019). Current perspectives on biosimilars. Journal of Industrial Microbiology and Biotechnology, 46(9–10), 1297–1311. https://doi.org/10.1007/s10295-019-02216-z
   PubMed Web of Science ®Google Scholar
• Ahmad, N., Morsley, K., Allard, A., Yein, K., Hall, K., Watson, E., Price, E., Collins, D., Ahmed, A., Carty, S., & Waller, R. (2019). Patient experience of switching to biosimilar benepali. Rheumatology (United Kingdom), 58(Supplement 3), iii166. https://doi.org/10.1093/rheumatology/kez110.013
   Google Scholar
• Åkesson, K. M., Saveman, B.-I., & Nilsson, G. (2007). Health care consumers’ experiences of information communication technology – a summary of literature. International Journal of Medical Informatics, 76(9), 633–645. https://doi.org/10.1016/j.ijmedinf.2006.07.001
   PubMed Web of Science ®Google Scholar
• Anjum, A. M., Ng, W. L., Sebastian, A., Devlin, J., & Fraser, A. (2019). Real life switching from infliximab innovator to biosimilar in rheumatic diseases: A 6-month single-centre prospective observational study. Fortune Journal of Rheumatology, 01((02|2)), 40–49. https://doi.org/10.26502/fjr.26880011
   Google Scholar
• Armuzzi, A., Avedano, L., Greveson, K., & Kang, T. (2019). Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: Education and communication strategies. Journal of Crohn's and Colitis, 13(2), 259–266. https://doi.org/10.1093/ecco-jcc/jjy150
   PubMed Web of Science ®Google Scholar
• Bartley, H., Faasse, K., Horne, R., & Petrie, K. J. (2016). You can't always get what you want: The influence of choice on nocebo and placebo responding. Annals of Behavioral Medicine, 50(3), 445–451. https://doi.org/10.1007/s12160-016-9772-1
   PubMed Web of Science ®Google Scholar
• Bernhardt, J. M. (2004). Communication at the core of effective public health. American Journal of Public Health, 94(12), 2051–2053. https://doi.org/10.2105/AJPH.94.12.2051
   PubMed Web of Science ®Google Scholar
• Betegnie, A. L., Gauchet, A., Lehmann, A., Grange, L., Roustit, M., Baudrant, M., Bedouch, P., & Allenet, B. (2016). Why do patients with chronic inflammatory rheumatic diseases discontinue their biologics? An assessment of patients’ adherence using a self-report questionnaire. The Journal of Rheumatology, 43(4), 724–730. https://doi.org/10.3899/jrheum.150414
   PubMed Web of Science ®Google Scholar
• Bhat, S., Altajar, S., Shankar, D., Zahorian, T., Robert, R., Qazi, T., Shah, B., & Farraye, F. A. (2020). Process and clinical outcomes of a biosimilar adoption program with infliximab-dyyb. Journal of Managed Care & Specialty Pharmacy, 26(4), 410–416. https://doi.org/10.18553/jmcp.2020.26.4.410
   PubMed Web of Science ®Google Scholar
• Boone, N. W., Liu, L., Romberg-Camps, M. J., Duijsens, L., Houwen, C., van der Kuy, P. H. M., Janknegt, R., Peeters, R., Landewe, R. B. M., Winkens, B., & van Bodegraven, A. A. (2018). The nocebo effect challenges the non-medical infliximab switch in practice. European Journal of Clinical Pharmacology, 74(5), 655–661. https://doi.org/10.1007/s00228-018-2418-4
   PubMed Web of Science ®Google Scholar
• Chan, A., Kitchen, J., Scott, A., Pollock, D., Marshall, R., & Herdman, L. (2019). Implementing and delivering a successful biosimilar switch programme – the Berkshire West experience. Future Healthcare Journal, 6(2), 143–145. https://doi.org/10.7861/futurehosp.6-2-143
   PubMedGoogle Scholar
• Chandra, S., Mohammadnezhad, M., & Ward, P. (2018). Trust and communication in a doctor-patient relationship: A literature review. Journal of Healthcare Communications, 3(3), https://doi.org/10.4172/2472-1654.100146
   Google Scholar
• Chau, J., Delate, T., Ota, T., & Bhardwaja, B. (2019). Patient perspectives on switching from infliximab to infliximab-dyyb in patients with rheumatologic diseases in the United States. ACR Open Rheumatology, 1(1), 52–57. https://doi.org/10.1002/acr2.1007
   PubMedGoogle Scholar
• Coget, E., Laffont-Lozes, P., Velasco Gonzalvo, V., Huc, D., Pineton De Chambrun, G., Altwegg, R., Blanc, P., Pageaux, G. P., Rosant, D., & Breuker, C. (2019). Establishment of a pharmaceutical standardised interview concerning biosimilars of infliximab in the daycare clinic of a gastroenterology department for patients affected by inflammatory bowel disease. European Journal of Hospital Pharmacy, 26, A136. https://doi.org/10.1136/ejhpharm-2019-eahpconf.293
   Google Scholar
• Colloca, L. (2017). Tell me the truth and I will not be harmed: Informed consents and nocebo effects. The American Journal of Bioethics, 17(6), 46–48. https://doi.org/10.1080/15265161.2017.1314057
   PubMed Web of Science ®Google Scholar
• Colloca, L., Panaccione, R., & Murphy, T. K. (2019). The clinical implications of nocebo effects for biosimilar therapy. Frontiers in Pharmacology, 10), https://doi.org/10.3389/fphar.2019.01372
   Web of Science ®Google Scholar
• Daller, J. (2016). Biosimilars: A consideration of the regulations in the United States and European Union. Regulatory Toxicology and Pharmacology, 76, 199–208. https://doi.org/10.1016/j.yrtph.2015.12.013
   PubMed Web of Science ®Google Scholar
• Danese, S., Fiorino, G., Raine, T., Ferrante, M., Kemp, K., Kierkus, J., Lakatos, P. L., Mantzaris, G., van der Woude, J., Panes, J., & Peyrin-Biroulet, L. (2017). ECCO position statement on the use of biosimilars for inflammatory bowel disease – an update. Journal of Crohn's and Colitis, 11(1), 26–34. https://doi.org/10.1093/ecco-jcc/jjw198
   PubMed Web of Science ®Google Scholar
• DeMarco, J., Nystrom, M., & Salvatore, K. (2011). The importance of patient education throughout the continuum of health care. Journal of Consumer Health On the Internet, 15(1), 22–31. https://doi.org/10.1080/15398285.2011.547069
   Google Scholar
• Ebbers, H. C., Pieper, B., Issa, A., Addison, J., Freudensprung, U., & Rezk, M. F. (2019). Real-world evidence on etanercept biosimilar SB4 in etanercept-naive or switching patients: A systematic review. Rheumatology and Therapy, 6(3), 317–338. https://doi.org/10.1007/s40744-019-00169-4
   PubMed Web of Science ®Google Scholar
• Edwards, C. J., Hercogová, J., Albrand, H., & Amiot, A. (2019). Switching to biosimilars: Current perspectives in immune-mediated inflammatory diseases. Expert Opinion on Biological Therapy, 19(10), 1001–1014. https://doi.org/10.1080/14712598.2019.1610381
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2019). Biosimilar medicines: Overview. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview.
   Google Scholar
• Faasse, K., Cundy, T., Gamble, G., & Petrie, K. J. (2013). The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects. Psychosomatic Medicine, 75(1), 90–96. https://doi.org/10.1097/PSY.0b013e3182738826
   PubMed Web of Science ®Google Scholar
• Faasse, K., Cundy, T., & Petrie, K. J. (2009). Thyroxine: Anatomy of a health scare. British Medical Journal, 339(dec29 1), b5613–b5613. https://doi.org/10.1136/bmj.b5613
   PubMedGoogle Scholar
• Faasse, K., Gamble, G., Cundy, T., & Petrie, K. J. (2012). Impact of television coverage on the number and type of symptoms reported during a health scare: A retrospective pre-post observational study. BMJ Open, 2(4),, e001607. https://doi.org/10.1136/bmjopen-2012-001607
   PubMed Web of Science ®Google Scholar
• Faasse, K., Grey, A., Jordan, R., Garland, S., & Petrie, K. J. (2015). Seeing is believing: Impact of social modeling on placebo and nocebo responding. Health Psychology, 34(8), 880–885. https://doi.org/10.1037/hea0000199
   PubMed Web of Science ®Google Scholar
• Faasse, K., & Petrie, K. J. (2013). The nocebo effect: Patient expectations and medication side effects. Postgraduate Medical Journal, 89(1055), 540–546. https://doi.org/10.1136/postgradmedj-2012-131730
   PubMed Web of Science ®Google Scholar
• Faasse, K., & Petrie, K. J. (2016). From me to you: The effect of social modelling on treatment outcomes. Current Directions in Psychological Science, 25(6), 438–443. https://doi.org/10.1177/0963721416657316
   Web of Science ®Google Scholar
• Ferrari, R., & Russell A. S. (2010). Effect of a symptom diary on symptom frequency and intensity in healthy subjects. The Journal of Rheumatology, 37(11), 2387–2389. https://doi.org/10.3899/jrheum.100513
   PubMed Web of Science ®Google Scholar
• Ferrario, A., Dedet, G., Humbert, T., Vogler, S., Suleman, F., & Pedersen, H. B. (2020). Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ, 368, l5444. https://doi.org/10.1136/bmj.l5444
   PubMedGoogle Scholar
• Fleischmann, R., Jairath, V., Mysler, E., Nicholls, D., & Declerck, P. (2020). Nonmedical switching from originators to biosimilars: Does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatology and Therapy, 7(1), 35–64. https://doi.org/10.1007/s40744-019-00190-7
   PubMed Web of Science ®Google Scholar
• Gasteiger, C., Jones, A. S. K., Kleinstauber, M., Lobo, M., Horne, R., Dalbeth, N., & Petrie, K. J. (2019). The effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthritis Care &Research, 24. https://doi.org/10.1002/acr.24012
   Google Scholar
• Gasteiger, C., Lobo, M., Dalbeth, N., & Petrie, K. J. (2020). Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Rheumatology International. https://doi.org/10.1007/s00296-020-04576-7
   PubMed Web of Science ®Google Scholar
• Germain, V., Scherlinger, M., Barnetche, T., & Schaeverbeke, T. (2020). Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: The weight of nocebo effect. Annals of the Rheumatic Diseases, 79(1), e11–e11. https://doi.org/10.1136/annrheumdis-2018-214374
   PubMed Web of Science ®Google Scholar
• Gherghescu, I., & Delgado-Charro, M. B. (2021). The biosimilar landscape: An overview of regulatory approvals by the EMA and FDA. Pharmaceutics, 13(1), 48. https://doi.org/10.3390/pharmaceutics13010048
   Web of Science ®Google Scholar
• Gisondi, P., Geat, D., Conti, A., Dapavo, P., Piaserico, S., De Simone, C., Bianchi, L., Costanzo, A., Malagoli, P., Malara, G., Micali, G., Naldi, L., Offidani, A., Patrizi, A., Prignano, F., Parodi, A., Rongioletti, F., Calzavara-Pinton, P., & Girolomoni, G. (2020). TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology, 16(6), 591–598. https://doi.org/10.1080/1744666X.2020.1771182
   PubMed Web of Science ®Google Scholar
• Glintborg, B., Sørensen, I. J., Loft, A. G., Lindegaard, H., Linauskas, A., Hendricks, O., Hansen, I. M. J., Jensen, D. V., Manilo, N., Espesen, J., Klarlund, M., Grydehøj, J., Dieperink, S. S., Kristensen, S., Olsen, J. S., Nordin, H., Chrysidis, S., Dalsgaard Pedersen, D., Sørensen, M. V., … Hetland, M. L. (2017). A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Annals of the Rheumatic Diseases, 76(8), 1426–1431. https://doi.org/10.1136/annrheumdis-2016-210742
   PubMed Web of Science ®Google Scholar
• Haghnejad, V., Le Berre, C., Dominique, Y., Zallot, C., Guillemin, F., & Peyrin-Biroulet, L. (2020). Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Digestive and Liver Disease, 52(3), 281–288. https://doi.org/10.1016/j.dld.2019.09.012
   Web of Science ®Google Scholar
• Hastier-De Chelle, A., Cluzeau, V., Condat, J., Arab, N., Hebuterne, X., & Filippi, J. (2019). P544 Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: A prospective study. Journal of Crohn's and Colitis, 13(Supplement 1), S386. https://doi.org/10.1093/ecco-jcc/jjy222.668
   Google Scholar
• Hemmington, A., Dalbeth, N., Jarrett, P., Fraser, A. G., Broom, R., Browett, P., & Petrie, K. J. (2017). Medical specialists’ attitudes to prescribing biosimilars. Pharmacoepidemiology and Drug Safety, 26(5), 570–577. https://doi.org/10.1002/pds.4186
   PubMed Web of Science ®Google Scholar
• Higgins, J. P., & Green, S. (2011). Cochrane handbook for systematic reviews of interventions (version 5.1.0.). The Cochrane Collaboration. http://www.cochrane-handbook.org/.
   Google Scholar
• Jacobs, I., Singh, E., Sewell, K. L., Al-Sabbagh, A., & Shane, L. G. (2016). Patient attitudes and understanding about biosimilars: An international cross-sectional survey. Patient Preference and Adherence, 10, 937–948. https://doi.org/10.2147/PPA.S104891
   PubMed Web of Science ®Google Scholar
• Joanna Briggs Institute. (2014). Reviewers’ manual, 2014. http://joannabriggs.org/.
   Google Scholar
• Jørgensen, K. K., Olsen, I. C., Goll, G. L., Lorentzen, M., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Mørk, C., Jahnsen, J., Kvien, T. K., Berset, I. P., Fevang, B. T., Florholmen, J., Kalstad, S., Mørk, N. J., Ryggen, K., Tveit, K. S., Sæther, S. K., Gulbrandsen, B., … Zettel, C. C. (2017). Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. The Lancet, 389(10086), 2304–2316. https://doi.org/10.1016/S0140-6736(17)30068-5
   PubMed Web of Science ®Google Scholar
• Jung, Y. S., Park, D. I., Kim, Y. H., Lee, J. H., Seo, P. J., Cheon, J. H., Kang, H. W., & Kim, J. W. (2015). Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. Journal of Gastroenterology and Hepatology, 30(12), 1705–1712. https://doi.org/10.1111/jgh.12997
   PubMed Web of Science ®Google Scholar
• Kay, J. (2020). Overcoming barriers to biosimilars in inflammatory arthritis. Nature Reviews Rheumatology, 16(2), 65–66. https://doi.org/10.1038/s41584-019-0359-7
   PubMed Web of Science ®Google Scholar
• Khaleel, I., Wimmer, B. C., Peterson, G. M., Zaidi, S. T. R., Roehrer, E., Cummings, E., & Lee, K. (2020). Health information overload among health consumers: A scoping review. Patient Education and Counseling, 103(1), 15–32. https://doi.org/10.1016/j.pec.2019.08.008
   PubMed Web of Science ®Google Scholar
• Kiltz, U., Tsiami, S., Baraliakos, X., & Braun, J. (2019). Non-medical switching from originator to biosimilar etanercept - no evidence for a relevant nocebo effect: A retrospective analysis of real-life data. Annals of the Rheumatic Diseases, 78(Supplement 2), 716–717. https://doi.org/10.1136/annrheumdis-2019-eular.2419
   PubMedGoogle Scholar
• Kim, H., Alten, R., Avedano, L., Dignass, A., Gomollon, F., Greveson, K., Halfvarson, J., Irving, P. M., Jahnsen, J., Lakatos, P. L., Lee, J., Makri, S., Parker, B., Peyrin-Biroulet, L., Schreiber, S., Simoens, S., Westhovens, R., Danese, S., & Jeong, J. H. (2020). The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases. Drugs, 80(2), 99–113. https://doi.org/10.1007/s40265-020-01256-5
   PubMed Web of Science ®Google Scholar
• Kovitwanichkanont, T., Raghunath, S., Wang, D., Kyi, L., Pignataro, S., Morton, S., Morand, E., & Leech, M. (2020). Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Internal Medicine Journal, 50(3), 374–377. https://doi.org/10.1111/imj.14753
   PubMed Web of Science ®Google Scholar
• Kristensen, L. E., Alten, R., Puig, L., Philipp, S., Kvien, T. K., Mangues, M. A., van den Hoogen, F., Pavelka, K., & Vulto, A. G. (2018). Non-pharmacological effects in switching medication: The nocebo effect in switching from originator to biosimilar agent. BioDrugs, 32(5), 397–404. https://doi.org/10.1007/s40259-018-0306-1
   PubMed Web of Science ®Google Scholar
• Layegh, Z., Ruwaard, J., Hebing, R. C. F., l’ Ami, M. J., van der Weele, W., Nurmohamed, M. T., Krieckaert, C., & Wolbink, G. (2019). Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. International Journal of Rheumatic Diseases, 22(5), 869–873. https://doi.org/10.1111/1756-185X.13512
   PubMed Web of Science ®Google Scholar
• Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 339(Jul 21), b2700–b2700. https://doi.org/10.1136/bmj.b2700
   PubMedGoogle Scholar
• MacKrill, K., Gamble, G., & Petrie, K. J. (2020). The effect of television and print news stories on the nocebo responding following a generic medication switch. Clinical Psychology in Europe, 2(2), 2623. https://doi.org/10.32872/cpe.v2i2.2623
   Google Scholar
• Madenidou, A. V., Jeffries, A., Varughese, S., Jones, S., Sari-Kouzel, H., Veevers, H., & Rao, C. (2019). Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature. Mediterranean Journal of Rheumatology, 30(Suppl 1), 69–75. https://doi.org/10.31138/mjr.30.1.69
   PubMedGoogle Scholar
• Metelli, S., & Chaimani, A. (2020). Challenges in meta-analyses with observational studies. Evidence-based Mental Health, 23(2), 83–87. https://doi.org/10.1136/ebmental-2019-300129
   PubMed Web of Science ®Google Scholar
• Mueller, M., D’Addario, M., Egger, M., Cevallos, M., Dekkers, O., Mugglin, C., & Scott, P. (2018). Methods to systematically review and meta-analyse observational studies: A systematic scoping review of recommendations. BMC Medical Research Methodology, 18(1), 44. https://doi.org/10.1186/s12874-018-0495-9
   PubMedGoogle Scholar
• Murdoch, B., & Caulfield, T. (2020). The law and ethics of switching from biologic to biosimilar in Canada. Journal of the Canadian Association of Gastroenterology, 3(5), 228–233. https://doi.org/10.1093/jcag/gwz043
   PubMedGoogle Scholar
• Müskens, W. D., Rongen-van Dartel, S. A., Teerenstra, S., Adang, E. M., & van Riel, P. L. (2020). One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology. Rheumatology Advances in Practice, 4(2), kaa042. https://doi.org/10.1093/rap/rkaa042
   Google Scholar
• Müskens, W. D., Rongen-van Dartel, S. A. A., Adang, E. M. M., & van Riel, P. (2019). Biosimilars in the management of chronic inflammatory diseases: The Dutch experience. Mediterranean Journal of Rheumatology, 30(Suppl 1), 76–81. https://doi.org/10.31138/mjr.30.1.76
   PubMedGoogle Scholar
• Nisar, M. K. (2019). Switching to biosimilar rituximab: A real world study. Rheumatology (United Kingdom), 58(Supplement 3), iii125–iii126. https://doi.org/10.1093/rheumatology/kez107.020
   Google Scholar
• Odinet, J. S., Day, C. E., Cruz, J. L., & Heindel, G. A. (2018). The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. Journal of Managed Care & Specialty Pharmacy, 24(10), 952–959. https://doi.org/10.18553/jmcp.2018.24.10.952
   PubMed Web of Science ®Google Scholar
• Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan – a web and mobile app for systematic reviews. Systematic Reviews, 5(1), 210. https://doi.org/10.1186/s13643-016-0384-4
   PubMedGoogle Scholar
• Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., Mikazane, H., Gutierrez-Ureña, S., Lim, M., Lee, Y. A., Lee, S. J., Kim, H., Yoo, D. H., & Braun, J. (2013). A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Annals of the Rheumatic Diseases, 72(10), 1605–1612. https://doi.org/10.1136/annrheumdis-2012-203091
   PubMed Web of Science ®Google Scholar
• Petit, J., Antignac, M., Poilverd, R. M., Dartout, S., Baratto, R., Louati, K., Deparis, N., Berenbaum, F., & Beauvais, C. (2019). How to reduce the nocebo effect when switching from originator infliximab to a biosimilar: Positive results of a multidisciplinary team intervention. Annals of the Rheumatic Diseases, 78(Supplement 2), 1447–1448. https://doi.org/10.1136/annrheumdis-2019-eular.7366
   Google Scholar
• Petitdidier, N., Tannoury, J., de'Angelis, N., Gagniere, C., Hulin, A., Rotkopf, H., Mesli, F., Brunetti, F., Sobhani, I., & Amiot, A. (2019). Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. Digestive and Liver Disease, 51(12), 1652–1660. https://doi.org/10.1016/j.dld.2019.08.020
   Web of Science ®Google Scholar
• Petrie, K. J., & Rief, W. (2019). Psychobiological mechanisms of placebo and nocebo effects: Pathways to improve treatments and reduce side effects. Annual Review of Psychology, 70(1), 599–625. https://doi.org/10.1146/annurev-psych-010418-102907
   PubMed Web of Science ®Google Scholar
• Plevris, N., Jones, G. R., Jenkinson, P. W., Lyons, M., Chuah, C. S., Merchant, L. M., Pattenden, R. J., Watson, E. F., Ho, G. T., Noble, C. L., Din, S., Shand, A. G., Arnott, I. D., & Lees, C. W. (2019). Implementation of CT-P13 via a managed switch programme in Crohn’s disease: 12-month real-world outcomes. Digestive Diseases and Sciences, 64(6), 1660–1667. https://doi.org/10.1007/s10620-018-5406-8
   PubMed Web of Science ®Google Scholar
• Pouillon, L., Socha, M., Demore, B., Thilly, N., Abitbol, V., Danese, S., & Peyrin-Biroulet, L. (2018). The nocebo effect: A clinical challenge in the era of biosimilars. Expert Review of Clinical Immunology, 14(9), 739–749. https://doi.org/10.1080/1744666X.2018.1512406
   PubMed Web of Science ®Google Scholar
• Ratnakumaran, R., To, N., Gracie, D. J., Selinger, C. P., O'Connor, A., Clark, T., Carey, N., Leigh, K., Bourner, L., Ford, A. C., & Hamlin, P. J. (2018). Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): A large single-centre experience. Scandinavian Journal of Gastroenterology, 53(6), 700–707. https://doi.org/10.1080/00365521.2018.1464203
   PubMed Web of Science ®Google Scholar
• Razanskaite, V., Bettey, M., Downey, L., Wright, J., Callaghan, J., Rush, M., Whiteoak, S., Ker, S., Perry, K., Underhill, C., Efrem, E., Admed, I., & Cummings, F. (2017). Biosimilar infliximab in inflammatory bowel disease: Outcomes of a managed switching programme. Journal of Crohn's and Colitis, 11(6), 690–696. https://doi.org/10.1093/ecco-jcc/jjw216
   PubMed Web of Science ®Google Scholar
• Rezk, M. F., & Pieper, B. (2017). Treatment outcomes with biosimilars: Be aware of the nocebo effect. Rheumatology and Therapy, 4(2), 209–218. https://doi.org/10.1007/s40744-017-0085-z
   PubMed Web of Science ®Google Scholar
• Rezk, M. F., & Pieper, B. (2018). To see or NOsee: The debate on the nocebo effect and optimizing the use of biosimilars. Advances in Therapy, 35(6), 749–753. https://doi.org/10.1007/s12325-018-0719-8
   PubMed Web of Science ®Google Scholar
• Robinson, S., Mekkayil, B., Hall, T., Heslop, P., & Walker, D. (2019). Patient experience of switching from enbrel to benapali. Rheumatology (United Kingdom), 58(Supplement 3), iii168. https://doi.org/10.1093/rheumatology/kez110.019
   Google Scholar
• Röder, H., Schnitzler, F., Borchardt, J., & Janelidze, S. (2018). Switch of infliximab originator to biosimilar CT-P13 in patients with crohn’s disease and ulcerative colitis in a large German IBD center. A one year, randomized and prospective trial. United European Gastroenterology Journal, 6 (Supplement 1), https://ueg.eu/.
   Google Scholar
• Sarnola, K., Merikoski, M., Jyrkka, J., & Hameen-Anttila, K. (2020). Physicians’ perceptions of the uptake of biosimilars: A systematic review. BMJ Open, 10(5), e034183. https://doi.org/10.1136/bmjopen-2019-034183
   PubMed Web of Science ®Google Scholar
• Scherer, R. W., & Saldanha, I. J. (2019). How should systematic reviewers handle conference abstracts? A view from the trenches. Systematic Reviews, 8(1), 264. https://doi.org/10.1186/s13643-019-1188-0
   PubMed Web of Science ®Google Scholar
• Scherlinger, M., Germain, V., Labadie, C., Barnetche, T., Truchetet, M. E., Bannwarth, B., Mehsen-Cetre, N., Richez, C., & Schaeverbeke, T. (2018). Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Joint, Bone, Spine, 85(5), 561–567. https://doi.org/10.1016/j.jbspin.2017.10.003
   PubMed Web of Science ®Google Scholar
• Scherlinger, M., Langlois, E., Germain, V., & Schaeverbeke, T. (2019). Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Seminars in Arthritis and Rheumatism, 48(5), 927–932. https://doi.org/10.1016/j.semarthrit.2018.07.005
   PubMed Web of Science ®Google Scholar
• Scherlinger, M., & Schaeverbeke, T. (2020). ‘To switch or not to switch’: The missing piece in the puzzle of biosimilar literature? Annals of the Rheumatic Diseases, 79(4), e36–e36. https://doi.org/10.1136/annrheumdis-2018-214908
   PubMed Web of Science ®Google Scholar
• Schmitz, E. M. H., Boekema, P. J., Straathof, J. W. A., van Renswouw, D. C., Brunsveld, L., Scharnhorst, V., van de Poll, M. E. C., Broeren, M. A. C., & Derijks, L. J. J. (2018). Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: A 12-month multicentre observational prospective cohort study. Alimentary Pharmacology & Therapeutics, 47(3), 356–363. https://doi.org/10.1111/apt.14453
   PubMed Web of Science ®Google Scholar
• Shakeel, S., Hassali, M. A., Rehman, H., Rehman, A. U., & Muneswarao, J. (2020). Knowledge, attitude, and practice towards biosimilars and interchangeable products: A prescriptive insight by the pharmacists. International Journal of General Medicine, Volume 13, 1075–1082. https://doi.org/10.2147/IJGM.S266545
   Web of Science ®Google Scholar
• Street, R. L., Makoul, G., Arora, N. K., & Epstein, R. M. (2009). How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Education and Counseling, 74(3), 295–301. https://doi.org/10.1016/j.pec.2008.11.015
   PubMed Web of Science ®Google Scholar
• Sullivan, E., Piercy, J., Waller, J., Black, C. M., Kachroo, S., & Nurmohamed, M. (2017). Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS ONE, 12(4), e0175826. https://doi.org/10.1371/journal.pone.0175826
   PubMed Web of Science ®Google Scholar
• Swedish Agency for Health Technology Assessment and Assessment of Social Services. (2016). Evaluation and synthesis of studies using qualitative methods of analysis. www.sbu.se/globalassets/ebm/metodbok/sbuhandbookqualitativemethodsofanalysis.pdf.
   Google Scholar
• Sweller, J. (1988). Cognitive load during problem solving: Effects on learning. Cognitive Science, 12(2), 257–285. https://doi.org/10.1207/s15516709cog1202_4
   Web of Science ®Google Scholar
• Tan, K., Petrie, K. J., Faasse, K., Bolland, M. J., & Grey, A. (2014). Unhelpful information about adverse drug reactions. BMJ, 349, g5019–g5019. https://doi.org/10.1136/bmj.g5019
   PubMedGoogle Scholar
• Tong, A., Sainsbury, P., & Craig, J. (2007). Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care, 19(6), 349–357. https://doi.org/10.1093/intqhc/mzm042
   PubMed Web of Science ®Google Scholar
• Tweehuysen, L., Huiskes, V. J. B., van den Bemt, B. J. F., Vriezekolk, J. E., Teerenstra, S., van den Hoogen, F. H. J., van den Ende, C. H., & den Broeder, A. A. (2018a). Open-label, non-mandatory transitioning from originator Etanercept to biosimilar SB4: Six-month results from a controlled cohort study. Arthritis and Rheumatology, 70(9), 1408–1418. https://doi.org/10.1002/art.40516
   PubMed Web of Science ®Google Scholar
• Tweehuysen, L., van den Bemt, B. J. F., van Ingen, I. L., de Jong, A. J. L., van der Laan, W. H., van den Hoogen, F. H. J., & den Broeder, A. A. (2018b). Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis and Rheumatology, 70(1), 60–68. https://doi.org/10.1002/art.40324
   PubMed Web of Science ®Google Scholar
• Uke, P. C., Morris, C., Chitale, S., James, J., Miller, H., & Gladston-Chelliah, E. (2019). Etanercept (ETN) biosimilar (benapali-SB4) switches in inflammatory arthritis patients at Wrightington hospital. Rheumatology (United Kingdom), 58(Supplement 3), iii164. https://doi.org/10.1093/rheumatology/kez110.006
   Google Scholar
• Ursin, H. (1997). Sensitization, somatization, and subjective health complaints. International Journal of Behavioral Medicine, 4(2), 105–116. https://doi.org/10.1207/s15327558ijbm0402_1
   PubMed Web of Science ®Google Scholar
• Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. G., & Huys, I. (2021). Informing patients about biosimilar medicines: The role of European patient associations. Pharmaceuticals, 14(2), 117. https://doi.org/10.3390/ph14020117
   Web of Science ®Google Scholar
• van Overbeeke, E., De Beleyr, B., de Hoon, J., Westhovens, R., & Huys, I. (2017). Perception of originator biologics and biosimilars: A survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs, 31(5), 447–459. https://doi.org/10.1007/s40259-017-0244-3
   PubMed Web of Science ®Google Scholar
• Voshaar, M. J., Nota, I., van de Laar, M. A., & van den Bemt, B. J. (2015). Patient-centred care in established rheumatoid arthritis. Best Practice & Research: Clinical Rheumatology, 29(4–5), 643–663. https://doi.org/10.1016/j.berh.2015.09.007
   PubMed Web of Science ®Google Scholar
• Waller, C. F., & Friganović, A. (2020). Biosimilars in oncology: Key role of nurses in patient education. Future Oncology, 16(25), 1931–1939. https://doi.org/10.2217/fon-2020-0486
   PubMed Web of Science ®Google Scholar
• Waller, J., Sullivan, E., Piercy, J., Black, C. M., & Kachroo, S. (2017). Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Preference and Adherence, 11, 519–530. https://doi.org/10.2147/PPA.S129333
   PubMed Web of Science ®Google Scholar
• Wells, R. E., & Kaptchuk, T. J. (2012). To tell the truth, the whole truth, may do patients harm: The problem of the nocebo effect for informed consent. The American Journal of Bioethics, 12(3), 22–29. https://doi.org/10.1080/15265161.2011.652798
   PubMed Web of Science ®Google Scholar
• Wilkins, A. R., Venkat, M. V., Brown, A. S., Dong, J. P., Ran, N. A., Hirsch, J. S., & Close, K. L. (2014). Patient perspectives on biosimilar insulin. Journal of Diabetes Science and Technology, 8(1), 23–25. https://doi.org/10.1177/1932296813515132
   PubMedGoogle Scholar
• Yoo, D. H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., Kovalenko, V., Prodanovic, N., Abello-Banfi, M., Gutierrez-Ureña, S., Morales-Olazabal, L., Tee, M., Jimenez, R., Zamani, O., Lee, S. J., Kim, H., Park, W., & Muller-Ladner, U. (2013). A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Annals of the Rheumatic Diseases, 72(10), 1613–1620. https://doi.org/10.1136/annrheumdis-2012-203090
   PubMed Web of Science ®Google Scholar
• Young, H. N., Len-Rios, M. E., Brown, R., Moreno, M. M., & Cox, E. (2017). How does patient-provider communication influence adherence to asthma medications? Patient Education and Counseling, 100(4), 696–702. https://doi.org/10.1016/j.pec.2016.11.022
   PubMed Web of Science ®Google Scholar